News
GSK
50.45
+0.52%
0.26
GSK Earnings Call Signals Strong Growth Despite Headwinds
TipRanks · 18h ago
Cigarette Sales Keep Falling. These 2 Tobacco Stocks Still Pay 5.5% Dividends
24/7 Wall St. · 1d ago
Measles cases rise to over 5,400 across US
Seeking Alpha · 2d ago
GSK Reports Positive CHMP Opinion for One-Dose Bexsero Booster
TipRanks · 2d ago
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
TipRanks · 3d ago
GSK Updates NASH Drug Study as Investors Await Results
TipRanks · 3d ago
GSK Reports Five PDMRs’ Share Reward Plan Acquisitions
TipRanks · 3d ago
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
TipRanks · 4d ago
U.S. measles elimination status is at risk as regional WHO body holds annual meeting
Seeking Alpha · 4d ago
GSK Investors Are Watching New Drug Launches -- Market Talk
Dow Jones · 4d ago
GlaxoSmithKline (GSK) Gets a Hold from Citi
TipRanks · 4d ago
Deutsche Bank Remains a Hold on GlaxoSmithKline (GSK)
TipRanks · 5d ago
Shionogi & Co.: Will Inorganic Growth Hurt Or Help Their 'Zoom Out Pivot'?
Seeking Alpha · 6d ago
A 17-Month High in the Dollar, and the Ten ADRhedged™ ETFs That Held Their Ground Against It
TipRanks · 6d ago
Weekly Report: what happened at GSK last week (1102-1106)?
Weekly Report · 6d ago
Wisconsin reports measles-linked infant death as U.S. cases top 5,000
Seeking Alpha · 11/06 17:18
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha · 11/06 17:13
GSK Publishes Provisional 2027 Dividend Schedule
TipRanks · 11/06 15:27
Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)
Seeking Alpha · 11/05 17:09
GSK Advances Early Ulcerative Colitis Study as Investors Watch Pipeline Potential
TipRanks · 11/05 16:34
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others.